Xeris Biopharma (XERS) Financials

$6.38 -0.05 (-0.78%)

Closing price 04:00 PM Eastern

Extended Trading

$6.38 0.00 (-0.08%)

As of 04:45 PM Eastern

Annual Income Statements for Xeris Biopharma

This table shows Xeris Biopharma's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024	2025
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-91	-123	-95	-62	-55	0.55
Consolidated Net Income / (Loss)	-91	-123	-95	-62	-55	0.55
Net Income / (Loss) Continuing Operations	-91	-123	-95	-62	-55	0.55
Total Pre-Tax Income	-91	-123	-96	-64	-57	0.55
Total Operating Income	-84	-115	-82	-44	-34	25
Total Gross Profit	11	36	88	135	166	249
Total Revenue	20	50	110	164	203	292
Operating Revenue	20	50	110	164	203	292
Total Cost of Revenue	9.05	13	23	29	37	43
Operating Cost of Revenue	9.05	13	23	29	37	43
Total Operating Expenses	95	151	170	179	200	224
Selling, General & Admin Expense	74	126	138	146	163	182
Research & Development Expense	21	25	21	22	26	31
Amortization Expense	0.00	0.55	11	11	11	11
Total Other Income / (Expense), net	-7.70	-7.57	-14	-19	-23	-24
Interest Expense	11	7.18	15	29	33	29
Interest & Investment Income	2.97	0.31	2.58	4.75	5.32	4.74
Other Income / (Expense), net	-0.01	-0.70	-1.40	5.20	4.40	0.00
Income Tax Expense	-0.11	0.00	-1.42	-1.25	-2.27	0.00
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)	0.01	0.04	-0.01	0.00	0.00	0.00
Basic Earnings per Share	($2.14)	($1.55)	($0.70)	($0.45)	($0.37)	$0.00
Weighted Average Basic Shares Outstanding	42.64M	79.03M	135.63M	137.67M	146.77M	160.43M
Diluted Earnings per Share	($2.14)	($1.55)	($0.70)	($0.45)	($0.37)	$0.00
Weighted Average Diluted Shares Outstanding	42.64M	79.03M	135.63M	137.67M	146.77M	172.74M
Weighted Average Basic & Diluted Shares Outstanding	42.64M	79.03M	137.29M	140.45M	153.94M	172.43M

This table shows Xeris Biopharma's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	-12	-13	-19	-15	-16	-5.13	-9.22	-1.93	0.62	11	2.23
Consolidated Net Income / (Loss)	-12	-13	-19	-15	-16	-5.11	-9.22	-1.93	0.62	11	2.23
Net Income / (Loss) Continuing Operations	-12	-13	-19	-15	-16	-5.11	-9.22	-1.93	0.62	11	2.23
Total Pre-Tax Income	-13	-14	-19	-14	-19	-5.11	-9.22	-1.93	0.62	11	2.23
Total Operating Income	-4.91	-9.84	-14	-8.19	-13	1.68	-3.09	4.48	6.73	17	7.92
Total Gross Profit	40	29	35	40	41	51	51	60	63	75	73
Total Revenue	48	44	41	48	54	60	60	72	74	86	83
Operating Revenue	48	44	41	48	54	60	60	72	74	86	83
Total Cost of Revenue	8.20	15	5.97	7.79	14	9.48	8.73	12	11	11	11
Operating Cost of Revenue	8.20	-	5.97	7.79	14	9.48	8.73	12	11	11	11
Total Operating Expenses	45	39	49	48	54	49	54	55	57	58	65
Selling, General & Admin Expense	37	38	38	40	45	40	44	44	46	48	53
Research & Development Expense	5.03	6.38	7.82	5.76	5.89	6.09	7.75	8.06	7.48	7.87	8.78
Amortization Expense	2.71	2.71	2.71	2.71	2.71	2.71	2.71	2.71	2.71	2.71	2.71
Total Other Income / (Expense), net	-7.61	-3.79	-4.43	-6.07	-6.17	-6.79	-6.13	-6.41	-6.11	-5.69	-5.68
Interest Expense	9.68	7.02	9.72	7.96	7.79	7.70	7.31	7.36	7.27	7.15	6.88
Interest & Investment Income	1.12	1.11	1.92	1.29	1.20	0.91	1.18	0.95	1.16	1.46	1.20
Income Tax Expense	-0.34	-0.24	0.31	0.75	-3.32	-	0.00	0.00	0.00	-	0.00
Basic Earnings per Share	($0.09)	($0.10)	($0.14)	($0.10)	($0.11)	($0.02)	($0.06)	($0.01)	$0.00	$0.07	$0.01
Weighted Average Basic Shares Outstanding	138.06M	137.67M	140.51M	148.35M	148.99M	146.77M	152.45M	159.46M	163.65M	160.43M	170.52M
Diluted Earnings per Share	($0.09)	($0.10)	($0.14)	($0.10)	($0.11)	($0.02)	($0.06)	($0.01)	$0.00	$0.07	$0.01
Weighted Average Diluted Shares Outstanding	138.06M	137.67M	140.51M	148.35M	148.99M	146.77M	152.45M	159.46M	177.62M	172.74M	177.63M
Weighted Average Basic & Diluted Shares Outstanding	138.12M	140.45M	148.26M	149.00M	149.08M	153.94M	160.16M	161.48M	165.92M	172.43M	172.64M

This table details how cash moves in and out of Xeris Biopharma's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024	2025
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	18	30	59	-55	4.07	39
Net Cash From Operating Activities	-81	-96	-103	-47	-37	29
Net Cash From Continuing Operating Activities	-81	-96	-103	-47	-37	29
Net Income / (Loss) Continuing Operations	-91	-123	-95	-62	-55	0.55
Consolidated Net Income / (Loss)	-91	-123	-95	-62	-55	0.55
Depreciation Expense	1.47	1.33	1.40	1.49	1.23	1.31
Amortization Expense	1.06	1.92	13	13	14	15
Non-Cash Adjustments To Reconcile Net Income	16	17	17	18	24	37
Changes in Operating Assets and Liabilities, net	-8.34	6.53	-39	-16	-21	-25
Net Cash From Investing Activities	-27	98	34	-6.00	4.88	-0.70
Net Cash From Continuing Investing Activities	-27	98	34	-6.00	4.88	-0.70
Purchase of Property, Plant & Equipment	-0.38	-1.09	-0.52	-2.26	-0.87	-0.70
Purchase of Investments	-102	-43	0.00	-44	-34	0.00
Sale and/or Maturity of Investments	75	104	35	40	40	0.00
Net Cash From Financing Activities	126	27	127	-1.61	36	11
Net Cash From Continuing Financing Activities	126	27	127	-1.61	36	11
Repayment of Debt	-31	0.00	-49	-1.19	-12	0.00
Issuance of Debt	95	0.00	146	0.00	50	0.00
Issuance of Common Equity	67	28	31	0.55	1.24	11
Other Financing Activities, net	0.07	-0.34	-0.46	-0.98	-3.25	0.70
Cash Interest Paid	4.56	7.29	11	28	27	27

This table details how cash moves in and out of Xeris Biopharma's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Change in Cash & Equivalents	-0.03	21	-4.76	-5.09	1.53	12	-13	0.85	32	19	0.71
Net Cash From Operating Activities	-15	7.47	-20	-10	-8.31	1.98	-10	0.18	18	20	9.87
Net Cash From Continuing Operating Activities	-15	7.47	-20	-10	-8.31	1.98	-10	0.18	18	20	9.87
Net Income / (Loss) Continuing Operations	-12	-13	-19	-15	-16	-5.11	-9.22	-1.93	0.62	11	2.23
Consolidated Net Income / (Loss)	-12	-13	-19	-15	-16	-5.11	-9.22	-1.93	0.62	11	2.23
Depreciation Expense	0.39	0.35	0.33	0.28	0.31	0.31	0.32	0.33	0.34	0.34	0.34
Amortization Expense	3.23	3.29	3.28	3.38	3.43	3.57	3.67	3.66	3.69	3.73	3.76
Non-Cash Adjustments To Reconcile Net Income	12	3.32	1.97	6.25	5.48	10	6.36	11	19	0.73	9.72
Changes in Operating Assets and Liabilities, net	-18	14	-6.89	-5.26	-1.78	-7.05	-11	-13	-4.82	4.28	-6.18
Net Cash From Investing Activities	15	15	-20	4.60	9.91	10	-0.01	-0.28	-0.07	-0.33	-0.33
Net Cash From Continuing Investing Activities	15	15	-20	4.60	9.91	10	-0.01	-0.28	-0.07	-0.33	-0.33
Purchase of Property, Plant & Equipment	-0.35	-0.13	-0.16	-0.40	-0.09	-0.22	-0.01	-0.28	-0.07	-0.33	-0.33
Net Cash From Financing Activities	-0.07	-1.23	35	0.66	-0.08	0.40	-3.14	0.94	14	-0.27	-8.84
Net Cash From Continuing Financing Activities	-0.07	-1.23	35	0.66	-0.08	0.40	-3.14	0.94	14	-0.27	-8.84
Issuance of Common Equity	-	-	-	-	-	0.53	0.00	-	9.17	0.69	7.33
Other Financing Activities, net	-0.07	-0.05	-2.98	-0.05	-0.08	-0.14	-3.14	0.11	4.68	-0.96	-16
Cash Interest Paid	6.86	5.62	1.50	6.82	13	6.02	0.00	13	7.08	6.95	5.35

This table presents Xeris Biopharma's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024	2025
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	159	304	345	323	323	384
Total Current Assets	152	143	187	156	168	240
Cash & Equivalents	38	67	122	67	72	111
Accounts Receivable	6.88	17	31	39	40	51
Inventories, net	8.35	18	25	39	48	69
Prepaid Expenses	3.20	4.59	9.29	5.78	7.45	9.55
Plant, Property, & Equipment, net	6.71	6.63	5.52	5.97	5.56	4.95
Total Noncurrent Assets	0.23	155	152	160	150	138
Goodwill	0.00	23	23	23	23	23
Intangible Assets	0.00	131	121	110	99	88
Other Noncurrent Operating Assets	0.23	0.83	8.72	28	28	27
Total Liabilities & Shareholders' Equity	159	304	345	323	323	384
Total Liabilities	125	209	299	329	353	370
Total Current Liabilities	28	79	74	95	100	110
Accounts Payable	3.12	8.92	4.61	12	2.29	3.08
Accrued Expenses	25	68	65	60	76	95
Other Current Liabilities	0.32	1.99	4.24	4.66	7.17	11
Total Noncurrent Liabilities	97	130	226	234	252	260
Long-Term Debt	87	88	187	191	217	220
Other Noncurrent Operating Liabilities	3.53	30	35	41	35	40
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	34	95	45	-6.78	-30	14
Total Preferred & Common Equity	34	95	45	-6.78	-30	14
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	34	95	45	-6.78	-30	14
Common Stock	371	555	600	610	642	685
Retained Earnings	-337	-460	-555	-617	-672	-671
Accumulated Other Comprehensive Income / (Loss)	0.01	-0.03	-0.02	-0.03	-0.03	-0.03

This table presents Xeris Biopharma's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026
Total Assets	303	321	329	328	337	332	321	315	335	370	392
Total Current Assets	149	166	156	158	173	170	163	163	186	224	252
Cash & Equivalents	84	51	46	46	63	58	59	58	59	92	112
Accounts Receivable	28	31	30	46	37	42	41	46	53	54	56
Inventories, net	20	29	37	38	41	43	45	53	67	67	74
Prepaid Expenses	7.85	11	8.31	7.97	7.64	7.36	7.14	6.03	5.96	11	9.40
Plant, Property, & Equipment, net	5.75	6.48	6.55	6.19	5.78	5.83	5.61	5.26	5.28	4.95	5.03
Total Noncurrent Assets	148	149	166	164	158	156	153	147	144	141	135
Goodwill	23	23	23	23	23	23	23	23	23	23	23
Intangible Assets	123	118	115	112	107	104	102	96	94	91	85
Other Noncurrent Operating Assets	2.17	8.62	28	28	28	28	28	28	27	28	27
Total Liabilities & Shareholders' Equity	303	321	329	328	337	332	321	315	335	370	392
Total Liabilities	248	291	315	324	346	351	349	351	354	371	379
Total Current Liabilities	69	81	80	87	73	75	91	95	95	116	119
Accounts Payable	3.92	12	12	12	7.09	5.80	7.45	6.35	9.46	6.53	11
Accrued Expenses	64	50	48	54	37	40	62	70	78	101	51
Other Current Liabilities	0.34	4.21	3.65	3.49	28	30	6.72	6.27	7.79	8.84	56
Total Noncurrent Liabilities	179	210	235	237	273	276	258	256	259	255	260
Long-Term Debt	139	188	188	190	230	230	216	218	219	219	221
Other Noncurrent Operating Liabilities	30	19	44	44	40	42	42	38	40	35	39
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	55	30	14	3.87	-9.18	-19	-28	-35	-19	-0.86	13
Total Preferred & Common Equity	55	30	14	3.87	-9.18	-19	-28	-35	-19	-0.86	13
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	55	30	14	3.87	-9.18	-19	-28	-35	-19	-0.86	13
Common Stock	597	602	605	608	627	632	638	646	664	682	682
Retained Earnings	-542	-572	-591	-604	-636	-651	-667	-681	-683	-682	-669
Accumulated Other Comprehensive Income / (Loss)	-0.04	-0.03	-0.08	-0.05	-0.04	-0.03	-0.02	-0.03	-0.02	-0.03	-0.02

This table displays calculated financial ratios and metrics derived from Xeris Biopharma's official financial filings.

Metric	2020	2021	2022	2023	2024	2025
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
DEI Shares Outstanding	-	-	-	-	-	165,924,289.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	165,924,289.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	0.00
Growth Metrics	-	-	-	-	-	-
Profitability Metrics	-	-	-	-	-	-
Net Operating Profit after Tax (NOPAT)	-58	-81	-57	-31	-24	25
Return On Investment Capital (ROIC_SIMPLE)	-	-	-24.70%	-15.16%	-11.63%	10.64%
Earnings before Interest and Taxes (EBIT)	-84	-116	-83	-39	-29	25
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-81	-113	-69	-25	-14	41
Valuation Ratios	-	-	-	-	-	-
Leverage & Solvency	-	-	-	-	-	-
Liquidity Ratios	-	-	-	-	-	-
Cash Flow Metrics	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-174	-87	-51	-24	33
Efficiency Ratios	-	-	-	-	-	-
Capital & Investment Metrics	-	-	-	-	-	-
Invested Capital	-13	81	110	131	131	123
Increase / (Decrease) in Invested Capital	0.00	94	29	21	0.06	-7.89
Book Value per Share	$0.79	$0.76	$0.33	($0.05)	($0.20)	$0.08
Tangible Book Value per Share	$0.79	($0.47)	($0.72)	($1.01)	($1.02)	($0.59)
Total Capital	121	183	232	203	202	234
Total Debt	87	88	187	210	232	220
Total Long-Term Debt	87	88	187	191	217	220
Net Debt	-47	-14	65	138	160	109
Capital Expenditures (CapEx)	0.38	1.09	0.52	2.26	0.87	0.70
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-9.78	-39	-8.77	7.73	11	20
Debt-free Net Working Capital (DFNWC)	124	64	113	80	82	131
Net Working Capital (NWC)	124	64	113	61	67	131
Net Nonoperating Expense (NNE)	33	42	37	31	31	24
Net Nonoperating Obligations (NNO)	-47	-14	65	138	160	109
Total Depreciation and Amortization (D&A)	2.53	3.25	14	14	15	16
Earnings Adjustments	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	($1.55)	($0.70)	($0.45)	($0.37)	$0.00
Adjusted Weighted Average Basic Shares Outstanding	0.00	135.52M	135.63M	137.67M	146.77M	160.43M
Adjusted Diluted Earnings per Share	$0.00	($1.55)	($0.70)	($0.45)	($0.37)	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	0.00	135.52M	135.63M	137.67M	146.77M	172.74M
Adjusted Basic & Diluted Earnings per Share	$0.00	($1.55)	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	79.03M	137.29M	140.45M	153.94M	172.43M
Normalized Net Operating Profit after Tax (NOPAT)	-58	-81	-57	-31	-24	17
Debt Service Ratios	-	-	-	-	-	-
Payout Ratios	-	-	-	-	-	-

This table displays calculated financial ratios and metrics derived from Xeris Biopharma's official financial filings.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
DEI Shares Outstanding	-	-	-	-	-	-	-	-	-	165,924,289.00	172,431,290.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	165,924,289.00	172,431,290.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	0.07	0.01
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	62.56%	33.93%	22.42%	26.46%	12.31%	35.39%	47.94%	48.84%	37.06%	-	38.27%
EBITDA Growth	97.75%	39.69%	15.17%	66.55%	-2,462.46%	236.54%	112.34%	315.97%	223.17%	-	1,239.46%
EBIT Growth	78.75%	28.19%	8.76%	50.15%	-214.66%	121.78%	71.58%	159.11%	153.96%	-	356.18%
NOPAT Growth	73.84%	35.13%	-7.29%	48.76%	-162.43%	117.06%	78.31%	154.75%	174.58%	-	465.97%
Net Income Growth	44.17%	-3.56%	-12.75%	24.38%	-29.12%	61.81%	51.42%	87.15%	103.95%	-	124.23%
EPS Growth	43.75%	0.00%	-16.67%	28.57%	-22.22%	80.00%	57.14%	90.00%	100.00%	-	116.67%
Operating Cash Flow Growth	17.71%	146.35%	22.33%	24.71%	43.16%	-73.56%	50.59%	101.76%	321.94%	-	198.40%
Free Cash Flow Firm Growth	55.74%	31.58%	85.27%	95.91%	106.60%	104.06%	36.55%	-43.64%	309.13%	-	615.67%
Invested Capital Growth	45.66%	18.60%	-2.44%	-2.72%	-8.41%	0.05%	1.51%	4.47%	-4.90%	-	-10.07%
Revenue Q/Q Growth	27.13%	-8.13%	-8.45%	18.28%	12.91%	10.74%	0.03%	19.00%	3.97%	-	-3.12%
EBITDA Q/Q Growth	97.09%	-1,095.01%	-78.43%	46.09%	-122.91%	163.68%	-83.88%	843.81%	27.13%	-	-42.34%
EBIT Q/Q Growth	73.94%	-94.63%	-40.95%	30.26%	-64.49%	113.47%	-283.93%	245.05%	50.18%	-	-52.81%
NOPAT Q/Q Growth	69.25%	-100.31%	-44.75%	42.53%	-57.48%	113.02%	-284.04%	245.05%	114.54%	-	-52.81%
Net Income Q/Q Growth	38.57%	-9.85%	-41.75%	20.94%	-4.89%	67.51%	-80.32%	79.09%	132.21%	-	-79.84%
EPS Q/Q Growth	35.71%	-11.11%	-40.00%	28.57%	-10.00%	81.82%	-200.00%	83.33%	100.00%	-	-85.71%
Operating Cash Flow Q/Q Growth	-6.30%	151.14%	-371.76%	49.03%	19.74%	123.78%	-607.90%	101.81%	10,027.47%	-	-50.76%
Free Cash Flow Firm Q/Q Growth	-1.31%	44.26%	75.88%	69.95%	263.45%	-65.76%	-477.40%	31.98%	565.54%	-	-12.31%
Invested Capital Q/Q Growth	5.83%	-10.30%	2.57%	-0.09%	-0.36%	-2.01%	4.07%	2.82%	-9.30%	-	-0.40%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	83.03%	65.93%	85.31%	83.79%	74.95%	84.23%	85.48%	83.37%	85.22%	-	87.28%
EBITDA Margin	-0.71%	-9.18%	-17.89%	-8.16%	-16.10%	9.26%	1.49%	11.83%	14.47%	-	14.45%
Operating Margin	-10.17%	-22.17%	-35.05%	-17.03%	-23.76%	2.79%	-5.14%	6.27%	9.05%	-	9.52%
EBIT Margin	-8.20%	-17.38%	-26.76%	-15.78%	-22.98%	2.80%	-5.14%	6.27%	9.05%	-	9.52%
Profit (Net Income) Margin	-25.23%	-30.16%	-46.71%	-31.22%	-29.00%	-8.51%	-15.34%	-2.70%	0.83%	-	2.69%
Tax Burden Percent	97.30%	98.27%	101.64%	105.25%	82.56%	100.00%	100.00%	100.00%	100.00%	-	100.00%
Interest Burden Percent	316.02%	176.62%	171.72%	188.00%	152.83%	-304.35%	298.38%	-43.02%	9.23%	-	28.22%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%
Return on Invested Capital (ROIC)	-8.84%	-21.10%	-30.95%	-15.91%	-22.31%	3.04%	-5.92%	7.87%	18.49%	-	23.18%
ROIC Less NNEP Spread (ROIC-NNEP)	-18.19%	-27.52%	-38.13%	-22.60%	-26.72%	-1.18%	-10.41%	4.63%	14.27%	-	19.13%
Return on Net Nonoperating Assets (RNNOA)	-57.77%	-145.22%	-458.31%	1,110.84%	332.00%	9.70%	73.92%	-37.54%	-141.66%	-	-242.93%
Return on Equity (ROE)	-66.60%	-166.32%	-489.26%	1,094.93%	309.69%	12.73%	68.00%	-29.67%	-123.18%	-	-219.75%
Cash Return on Invested Capital (CROIC)	-65.26%	-42.57%	-20.70%	-16.40%	-13.85%	-18.05%	-13.15%	-9.39%	10.29%	-	38.36%
Operating Return on Assets (OROA)	-3.97%	-8.54%	-13.94%	-8.67%	-13.27%	1.76%	-3.51%	4.63%	6.97%	-	8.48%
Return on Assets (ROA)	-12.21%	-14.82%	-24.33%	-17.15%	-16.75%	-5.35%	-10.47%	-1.99%	0.64%	-	2.39%
Return on Common Equity (ROCE)	-66.60%	-166.32%	-489.26%	1,094.93%	309.69%	12.73%	68.00%	-29.67%	-123.18%	-	-219.75%
Return on Equity Simple (ROE_SIMPLE)	-1,598.84%	0.00%	701.69%	308.85%	222.83%	0.00%	128.32%	0.00%	0.00%	-	0.00%
Net Operating Profit after Tax (NOPAT)	-3.44	-6.89	-9.97	-5.73	-9.03	1.18	-2.16	3.14	6.73	17	7.92
NOPAT Margin	-7.12%	-15.52%	-24.54%	-11.92%	-16.63%	1.96%	-3.60%	4.39%	9.05%	-	9.52%
Net Nonoperating Expense Percent (NNEP)	9.36%	6.41%	7.18%	6.68%	4.42%	4.22%	4.49%	3.24%	4.22%	-	4.05%
Return On Investment Capital (ROIC_SIMPLE)	-	-3.39%	-	-	-	0.58%	-1.11%	1.57%	3.08%	7.17%	3.38%
Cost of Revenue to Revenue	16.97%	34.07%	14.69%	16.21%	25.05%	15.77%	14.52%	16.63%	14.78%	-	12.72%
SG&A Expenses to Revenue	77.17%	84.63%	94.44%	83.21%	82.86%	66.79%	73.22%	62.05%	62.46%	-	63.93%
R&D to Revenue	10.42%	14.38%	19.25%	11.98%	10.85%	10.14%	12.90%	11.26%	10.06%	-	10.57%
Operating Expenses to Revenue	93.20%	88.10%	120.36%	100.83%	98.71%	81.44%	90.62%	77.10%	76.17%	-	77.76%
Earnings before Interest and Taxes (EBIT)	-3.96	-7.72	-11	-7.58	-12	1.68	-3.09	4.48	6.73	17	7.92
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-0.34	-4.08	-7.27	-3.92	-8.74	5.56	0.90	8.47	11	21	12
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	66.44	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	76.87
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Price to Revenue (P/Rev)	1.68	1.98	1.81	1.84	2.27	2.49	3.80	3.04	4.94	-	3.18
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	83.29
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	1.20%
Enterprise Value to Invested Capital (EV/IC)	2.73	3.53	3.38	3.63	4.39	5.09	7.46	6.48	11.36	-	9.06
Enterprise Value to Revenue (EV/Rev)	2.61	2.82	2.65	2.68	3.13	3.28	4.57	3.69	5.42	-	3.52
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	146.59	56.14	-	21.31
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	147.13	-	30.91
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	210.21	-	30.91
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	136.61	-	22.87
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	107.55	-	22.36
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	53.80	-30.97	-25.14	-11.97	-8.17	-7.84	-6.54	-11.33	-254.90	-	17.00
Long-Term Debt to Equity	49.27	-28.15	-25.02	-11.95	-7.63	-7.33	-6.20	-11.33	-254.90	-	17.00
Financial Leverage	3.18	5.28	12.02	-49.16	-12.42	-8.19	-7.10	-8.10	-9.93	-	-12.70
Leverage Ratio	10.71	17.37	31.53	-117.01	-26.53	-17.74	-14.72	-17.27	-23.69	-	-31.99
Compound Leverage Factor	33.84	30.68	54.14	-219.97	-40.55	53.99	-43.91	7.43	-2.19	-	-9.03
Debt to Total Capital	98.18%	103.34%	104.14%	109.11%	113.95%	114.63%	118.05%	109.68%	100.39%	-	94.45%
Short-Term Debt to Total Capital	8.27%	9.40%	0.46%	0.20%	7.42%	7.46%	6.14%	0.00%	0.00%	-	0.00%
Long-Term Debt to Total Capital	89.90%	93.94%	103.68%	108.92%	106.54%	107.17%	111.90%	109.68%	100.39%	-	94.45%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%
Common Equity to Total Capital	1.82%	-3.34%	-4.14%	-9.11%	-13.95%	-14.63%	-18.05%	-9.68%	-0.39%	-	5.55%
Debt to EBITDA	-7.59	-8.50	-9.86	-14.79	-9.64	-16.16	-37.08	35.32	8.54	-	4.25
Net Debt to EBITDA	-5.18	-5.57	-6.12	-9.82	-6.74	-11.17	-27.65	25.75	4.98	-	2.10
Long-Term Debt to EBITDA	-6.95	-7.73	-9.81	-14.77	-9.01	-15.11	-35.15	35.32	8.54	-	4.25
Debt to NOPAT	-6.02	-6.82	-7.33	-8.87	-7.32	-9.86	-14.59	-31.80	31.99	-	6.16
Net Debt to NOPAT	-4.11	-4.47	-4.55	-5.89	-5.12	-6.81	-10.88	-23.18	18.64	-	3.05
Long-Term Debt to NOPAT	-5.51	-6.20	-7.29	-8.85	-6.84	-9.21	-13.83	-31.80	31.99	-	6.16
Altman Z-Score	-1.42	-1.43	-1.35	-1.36	-1.45	-1.16	-0.64	-0.49	0.67	-	0.47
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.82	1.64	2.37	2.26	1.79	1.67	1.72	1.95	1.93	-	2.12
Quick Ratio	1.29	1.17	1.71	1.59	1.21	1.12	1.10	1.18	1.25	-	1.42
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-49	-27	-6.61	-1.99	3.25	1.11	-4.19	-2.85	13	25	22
Operating Cash Flow to CapEx	-4,234.78%	5,659.85%	-12,379.88%	-2,606.55%	-9,545.98%	897.73%	-77,161.54%	65.23%	25,960.56%	-	3,036.92%
Free Cash Flow to Firm to Interest Expense	-5.08	-3.90	-0.68	-0.25	0.42	0.14	-0.57	-0.39	1.83	-	3.14
Operating Cash Flow to Interest Expense	-1.51	1.06	-2.09	-1.30	-1.07	0.26	-1.37	0.02	2.54	-	1.43
Operating Cash Flow Less CapEx to Interest Expense	-1.54	1.05	-2.11	-1.35	-1.08	0.23	-1.37	-0.01	2.53	-	1.39
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.48	0.49	0.52	0.55	0.58	0.63	0.68	0.74	0.77	-	0.89
Accounts Receivable Turnover	4.16	4.68	5.02	4.99	4.30	5.10	5.32	5.15	5.61	-	6.14
Inventory Turnover	0.68	0.90	0.84	0.93	1.02	0.85	0.85	0.79	0.73	-	0.70
Fixed Asset Turnover	25.58	28.54	27.95	29.30	31.76	35.22	40.31	44.26	50.41	-	61.18
Accounts Payable Turnover	2.48	3.54	3.07	4.26	4.35	5.32	5.89	5.73	5.88	-	4.99
Days Sales Outstanding (DSO)	87.84	77.97	72.71	73.10	84.84	71.55	68.67	70.83	65.07	-	59.49
Days Inventory Outstanding (DIO)	536.73	405.03	435.53	391.28	357.71	431.14	431.34	460.50	499.90	-	521.53
Days Payable Outstanding (DPO)	147.34	103.03	118.84	85.72	83.90	68.65	61.98	63.73	62.07	-	73.22
Cash Conversion Cycle (CCC)	477.24	379.97	389.41	378.67	358.66	434.04	438.02	467.59	502.90	-	507.79
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	146	131	134	134	134	131	136	140	127	123	122
Invested Capital Turnover	1.24	1.36	1.26	1.33	1.34	1.55	1.65	1.80	2.04	-	2.43
Increase / (Decrease) in Invested Capital	46	21	-3.36	-3.75	-12	0.06	2.03	5.99	-6.55	-7.89	-14
Enterprise Value (EV)	399	462	454	487	587	666	1,016	907	1,442	-	1,110
Market Capitalization	257	325	310	334	425	505	845	748	1,314	-	1,000
Book Value per Share	$0.03	($0.05)	($0.07)	($0.13)	($0.19)	($0.20)	($0.23)	($0.12)	($0.01)	$0.08	$0.08
Tangible Book Value per Share	($0.95)	($1.01)	($0.99)	($0.99)	($1.03)	($1.02)	($1.00)	($0.85)	($0.71)	($0.59)	($0.55)
Total Capital	212	203	222	212	203	202	195	199	219	234	234
Total Debt	208	210	231	231	231	232	230	219	219	220	221
Total Long-Term Debt	190	191	230	230	216	217	218	219	219	220	221
Net Debt	142	138	143	153	162	160	171	159	128	109	109
Capital Expenditures (CapEx)	0.35	0.13	0.16	0.40	0.09	0.22	0.01	0.28	0.07	0.33	0.33
Debt-free, Cash-free Net Working Capital (DFCFNWC)	23	7.73	14	18	17	11	22	31	16	20	21
Debt-free Net Working Capital (DFNWC)	89	80	101	95	87	82	80	90	108	131	133
Net Working Capital (NWC)	71	61	100	95	72	67	68	90	108	131	133
Net Nonoperating Expense (NNE)	8.75	6.50	9.01	9.27	6.71	6.29	7.06	5.07	6.11	5.69	5.68
Net Nonoperating Obligations (NNO)	142	138	143	153	162	160	171	159	128	109	109
Total Depreciation and Amortization (D&A)	3.62	3.64	3.60	3.66	3.74	3.88	3.99	3.98	4.03	4.06	4.10
Debt-free, Cash-free Net Working Capital to Revenue	14.77%	4.72%	8.09%	9.76%	9.31%	5.27%	9.86%	12.65%	6.09%	-	6.78%
Debt-free Net Working Capital to Revenue	57.99%	48.92%	59.07%	52.52%	46.35%	40.54%	36.12%	36.75%	40.51%	-	42.27%
Net Working Capital to Revenue	46.51%	37.26%	58.47%	52.29%	38.31%	33.10%	30.74%	36.75%	40.51%	-	42.27%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.09)	($0.10)	($0.14)	($0.10)	($0.11)	($0.02)	($0.06)	($0.01)	$0.00	$0.07	$0.01
Adjusted Weighted Average Basic Shares Outstanding	138.06M	137.67M	140.51M	148.35M	148.99M	146.77M	152.45M	159.46M	163.65M	160.43M	170.52M
Adjusted Diluted Earnings per Share	($0.09)	($0.10)	($0.14)	($0.10)	($0.11)	($0.02)	($0.06)	($0.01)	$0.00	$0.07	$0.01
Adjusted Weighted Average Diluted Shares Outstanding	138.06M	137.67M	140.51M	148.35M	148.99M	146.77M	152.45M	159.46M	177.62M	172.74M	177.63M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	138.12M	140.45M	148.26M	149.00M	149.08M	153.94M	160.16M	161.48M	165.92M	172.43M	172.64M
Normalized Net Operating Profit after Tax (NOPAT)	-3.44	-6.89	-9.97	-5.73	-9.03	1.18	-2.16	3.14	4.71	12	5.54
Normalized NOPAT Margin	-7.12%	-15.52%	-24.54%	-11.92%	-16.63%	1.96%	-3.60%	4.39%	6.33%	-	6.67%
Pre Tax Income Margin	-25.93%	-30.70%	-45.95%	-29.66%	-35.13%	-8.51%	-15.34%	-2.70%	0.83%	-	2.69%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-0.41	-1.10	-1.12	-0.95	-1.60	0.22	-0.42	0.61	0.93	-	1.15
NOPAT to Interest Expense	-0.36	-0.98	-1.03	-0.72	-1.16	0.15	-0.30	0.43	0.93	-	1.15
EBIT Less CapEx to Interest Expense	-0.45	-1.12	-1.14	-1.00	-1.61	0.19	-0.42	0.57	0.92	-	1.10
NOPAT Less CapEx to Interest Expense	-0.39	-1.00	-1.04	-0.77	-1.17	0.12	-0.30	0.39	0.92	-	1.10
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%

Financials Breakdown Chart

Key Financial Trends

Here are the top trends for Xeris Biopharma (XERS) based on quarterly statements from the last four years. The bullets are organized with positives first, then neutral observations, then negatives.

Q4 2025: Consolidated Net Income / (Loss) rose to 11,081,000, marking a profitable quarter after a stretch of losses in 2025.
Q4 2025: Gross margin remained very strong, with Gross Profit of 74,860,000 on Revenue of 85,807,000 (about 87%).
Q4 2025: Operating Income was positive at 16,773,000, indicating improved operating leverage.
Q4 2025: Net Cash From Continuing Operating Activities was 20,156,000 and Net Change in Cash was 19,444,000, signaling stronger near-term liquidity.
Q3 2025: Cash and cash equivalents were about 91.6 million, up from about 59.3 million in Q2 2025, reflecting improving liquidity through 2025.
Total assets rose to about 370.2 million by Q3 2025 from about 334.7 million in Q2 2025, indicating balance-sheet growth.
Long-term debt remained high in the 217–219 million range in 2025, suggesting ongoing leverage considerations for investors.
Negative shareholders’ equity persisted in early 2025 (Q1 2025: total equity around -35.1 million), improving to around -0.86 million by Q3 2025, highlighting a lingering balance-sheet deficit.
Profitability remained volatile in 2025, with Q1 2025 net income continuing operations at -9,220,000 and Q2 2025 at -1,928,000 before the Q4 rebound.
Interest expense remained a drag, roughly 7.15 million in Q4 2025, keeping net income pressure even as gross margins stay high.

05/14/26 04:47 PM ETAI Generated. May Contain Errors.

Xeris Biopharma Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Xeris Biopharma's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Xeris Biopharma's net income appears to be on a downward trend, with a most recent value of $554 thousand in 2025, falling from -$91.14 million in 2020. The previous period was -$54.84 million in 2024. See where experts think Xeris Biopharma is headed by visiting Xeris Biopharma's forecast page.

Xeris Biopharma's total operating income in 2025 was $24.90 million, based on the following breakdown:

Total Gross Profit: $249.28 million
Total Operating Expenses: $224.38 million

Over the last 5 years, Xeris Biopharma's total revenue changed from $20.16 million in 2020 to $291.85 million in 2025, a change of 1,348.0%.

Xeris Biopharma's total liabilities were at $369.84 million at the end of 2025, a 4.9% increase from 2024, and a 195.0% increase since 2020.

In the past 5 years, Xeris Biopharma's cash and equivalents has ranged from $37.60 million in 2020 to $121.97 million in 2022, and is currently $111.04 million as of their latest financial filing in 2025.

Over the last 5 years, Xeris Biopharma's book value per share changed from 0.79 in 2020 to 0.08 in 2025, a change of -89.6%.

Related Companies

Financial statements for NASDAQ:XERS last updated on 5/12/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Xeris Biopharma (XERS) Financials

Financials Breakdown Chart

Key Financial Trends

Xeris Biopharma Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Xeris Biopharma (XERS) Financials

Annual Income Statements for Xeris Biopharma

Quarterly Income Statements for Xeris Biopharma

Annual Cash Flow Statements for Xeris Biopharma

Quarterly Cash Flow Statements for Xeris Biopharma

Annual Balance Sheets for Xeris Biopharma

Quarterly Balance Sheets for Xeris Biopharma

Annual Metrics And Ratios for Xeris Biopharma

Quarterly Metrics And Ratios for Xeris Biopharma

Financials Breakdown Chart

Key Financial Trends

Xeris Biopharma Financials - Frequently Asked Questions

When does Xeris Biopharma's financial year end?

How has Xeris Biopharma's net income changed over the last 5 years?

What is Xeris Biopharma's operating income?

How has Xeris Biopharma's revenue changed over the last 5 years?

How much debt does Xeris Biopharma have?

How much cash does Xeris Biopharma have?

How has Xeris Biopharma's book value per share changed over the last 5 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools